Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia
There is limited real-world data regarding the effectiveness of asciminib after one prior tyrosine kinase inhibitor (TKI) in chronic-phase chronic myeloid leukemia (CML-CP). In this US physician panel-based chart review, nearly all patients (95 %) remained on asciminib and 68 % achieved or maintained a major molecular response at 48 weeks, suggesting that asciminib is well-tolerated and effective after one prior TKI.
Authors
- Carmine Rossi (ORCID: https://orcid.org/0000-0001-5801-6927)
- Remi Bellefleur (ORCID: https://orcid.org/0000-0001-9540-9519)
- Kejal Parikh (ORCID: https://orcid.org/0000-0001-8556-0012)
- David Wei
- Islam Sadek (ORCID: https://orcid.org/0000-0002-1072-4585)
- Andrea Damon
- Ehab L. Atallah (ORCID: https://orcid.org/0000-0002-9919-3564)
- Dominick Latrémouille-Viau (ORCID: https://orcid.org/0000-0002-8565-9220)
- Daisy Yang
- Annie Guérin
Institutions
- Medical College of Wisconsin (US)
- Novartis (United States) (US)
Publication Details
- Journal
- Leukemia Research
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1016/j.leukres.2025.108089
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Novartis Pharmaceuticals Corporation